David A. Baker, Ph.D.
David Baker cofounded Promentis Pharmaceuticals in 2007, currently serves as a Director and chairs the Scientific Advisory Board. Dr. Baker is also Professor and Associate Chair in the Department of Biomedical Sciences at Marquette University. He previously served as a postdoctoral fellow at the Medical University of South Carolina in the laboratory of Peter Kalivas. Dr. Baker earned his Ph.D. at Arizona State University in 1999 and his B.S. at Montana State University in 1992 working in the laboratories of Dr. Janet Neisewander and Dr. Michael Babcock, respectively. He has had an active research career examining the neurobiological basis of diseases of the brain. Since 2001, his research has focused on identifying novel therapeutic targets capable of normalizing brain circuitry that underlies compulsive disorders. During this time, Dr. Baker pioneered research implicating system xc- as a key component of pathological glutamate signaling; work that served as the scientific basis for Promentis Pharmaceuticals. His achievements have been featured in the Marquette Magazine cover story (Winter 2009 issue)"Searching for a Cure for the Brain's Darkest Diseases" and earned him the 2010 Daniel X. Freedman Award from NARSAD for outstanding basic research achievement. In addition, he has been the recipient of the Milwaukee Health Care Award in 2012 and The Business Journal's Forty under 40 Award in 2010, honoring Milwaukee's up-and-coming leaders.
Peter W. Kalivas, Ph.D.
Dr. Kalivas is Professor and Chair of the Department of Neurosciences at the Medical University of South Carolina in Charleston (1998-present). He is best known for his work to elucidate the brain molecules and neurocircuitry that underlie addiction, with a focus on characterizing the neuroplasticity produced by chronic use of addictive drugs in the prefrontal cortex and its glutamatergic projections to the basal ganglia. Dr. Kalivas’ work is highlighted in over 400 publications and Dr. Kalivas has served as editor of six books that focus on the cellular mechanisms and brain circuitry mediating psychiatric disorders. He has received a great number of national and international awards and is a Distinguished University Professor at both the Medical University of South Carolina and Washington State University. He is a member of the Scientific Advisory Board for the National Alliance for Research in Schizophrenia and Depression, and chairs the Scientific Advisory Board for the Medications Development Program in the National Institute on Drug Abuse. He also serves as editor or is on the editorial board of six major journals in the field of neuroscience. He received his Ph.D. in Pharmacology from the University of Washington in Seattle in 1980.
Daniel C. Javitt, M.D., Ph.D.
Dr. Javitt is a Professor in the Department of Psychiatry and Neuroscience at the Columbia University College of Physicians and Surgeons. He was an early proponent of the NMDA model of schizophrenia and is a leader in NMDA-based treatment development. He has published over 200 original research articles on topics related to schizophrenia, with over 4400 cumulative citations. He has received numerous honors for his work, including research awards from the American Psychiatric Association, the American College of Neuropsychopharmacology, the Society for Biological Psychiatry, and the Child Welfare League of America. His work has been supported by the National Institute of Health, NARSAD and the Stanley Foundation.
Herbert Y. Meltzer, M.D.
Dr. Meltzer is Professor in Psychiatry and Behavioral Sciences and Physiology at Northwestern University Keinberg School of Medicine in Chicago. He is also chair of the Young Investigator Grant Review Committee for NARSAD. He is chairman of the International Psychopharmacology Algorithm Project (www.IPAP.org). Dr. Meltzer received his BA from Cornell University, an MA in Chemistry from Harvard, and his MD from Yale University. Dr. Meltzer has been President of the American College of Neuropsychopharmacology (ACNP) and the Collegium International Neuro-psychopharmacologicum (CINP). He served as editor of Psychopharmacology: The Third Generation of Progress and co-editor of the ACNP journal, Neuropsychopharmacology, and is a member of the editorial board of numerous scientific journals. Dr. Meltzer is the recipient of a great number of awards and prizes. His research interests include: clinical and basic psychopharmacology, with an emphasis on antipsychotic drug efficacy, safety and tolerability, the mechanism of action of antipsychotic drugs, genetic factors in schizophrenia and pharmacogenomics, prevention of suicide in schizophrenia, and cognitive impairment in schizophrenia.
Chad E. Beyer, Ph.D., MBA
Chad Beyer is President & CEO of Promentis. He has nearly 20 years of experience in the research, discovery and business development of medications aimed to treat CNS and neurological disorders. Prior to joining Promentis, Dr. Beyer served as the Head of Neurochemistry and led the Psychiatry Task Force at Wyeth Pharmaceuticals in Princeton, NJ. During his career at Wyeth, Dr. Beyer led several early-stage drug discovery teams and managed a group responsible for contributing to the commercialization and life-cycle management of two blockbuster medications: Effexor® and Pristiq®. Dr. Beyer holds a Ph.D. in Neuropharmacology from LSU Medical Center and an MBA from the Rutgers Business School. Notably, Dr. Beyer has authored more than 70 manuscripts, 3 patents, co-edited "Next Generation Antidepressants" and is co-founder of the journal "Technology Transfer & Entrepreneurship." Dr. Beyer is also an adjunct faculty member at Thomas Jefferson University in Philadelphia where he teaches "Bioventure Management", a class focused on the business of doing science.
Michael P. Neary, B.S.
Michael Neary is currently Director of Research & Development at Promentis. Since beginning work at Promentis in 2010, Mr. Neary has taken on an increasingly important role within the company; he now oversees the Promentis day-to-day research efforts, coordinates the activities of Promentis' collaborators, and continues to work toward advancing Promentis' scientific platform and lead molecules closer to the patients who suffer from these devastating disorders. Prior to joining Promentis, Mr. Neary worked at Roche Madison on programs focused on the development of RNAi delivery platforms. Mr. Neary holds a Biochemistry degree from the University of Wisconsin (Madison).
Sheldon Garrison, Ph.D.
Dr. Garrison joined Promentis in 2014 and serves as Director of Pediatric and Rare Diseases. He has 11 years of neuroscience research experience that has focused on neuromuscular development, sensory biology and pain. Dr. Garrison earned a Ph.D. in Biological Sciences from the University of Wisconsin – Milwaukee and a B.S. from the University of Wisconsin – Madison. He has received multiple competitive financial awards and has authored eight publications over the past four years. Dr. Garrison has previously worked as a Postdoctoral fellow at the Medical College of Wisconsin and has held biotech consulting positions with the Postdoc Industry Consultants (PICO), DNASTAR, Inc and Sequencing Singapore. Dr. Garrison has also served as an instructor at the University of Wisconsin – Milwaukee and Milwaukee Area Technical College.
Promentis understands the importance of, and strength in, collaborating with local industry and higher educational institutions. Therefore we continually seek to work with aspiring scientists to help advance our drug development program. Since 2012, our R&D team has enlisted the services of PICO, a biotech consulting group comprised of postdoctoral fellows from the Medical College of Wisconsin and University of Wisconsin-Milwaukee. Additionally, our ambitious interns exemplify our core values in drug development while gaining real-world experience working in a company that is helping to improve patients’ lives.
Click here to learn more about PICO.